Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
94.3 EUR | -1.05% | -1.00% | -6.26% |
May. 10 | BioMérieux: the rebound gains momentum, an analyst reinforces its case | CF |
Apr. 26 | BioMérieux: share price rises, analyst remains Buy | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.26% | 12.23B | B+ | ||
-3.93% | 8.17B | B- | ||
+7.10% | 5.78B | B | ||
+30.16% | 5.74B | C | ||
-7.47% | 4.24B | C | ||
-57.20% | 2.97B | D+ | ||
+12.56% | 2.73B | - | - | |
-4.67% | 2.38B | B- | ||
+27.38% | 2.26B | C | ||
-4.21% | 1.87B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIM Stock
- Ratings bioMérieux